Evolving technology platforms in pharma-biotech (TechVision) — industry analysis, trends, technologies & opportunities
Research and Markets has announced the addition of the "Evolving Technology Platforms in Pharma-Biotech (TechVision)" report to their offering.
This comprehensive report provides a detailed understanding of the evolving technology platforms in the pharma-biotech industry, offer readers an in-depth analysis of the key topics all market participants should be aware of. It considers current and future factors expected to play a part in this market's development. It also considers the various drivers, challenges and opportunities of the industry.
Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease. This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or first-in-human studies.
The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines. Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society.
The RS also includes: R&D portfolio and budgetary analysis Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones Strategic evaluation of R&D portfolio
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance